Citation Impact
Citing Papers
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
2008 Standout
Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
2008
Rosuvastatin in the management of hyperlipidemia
2004
CIRCADIAN RHYTHM OF DOUBLE (RATE-PRESSURE) PRODUCT IN HEALTHY NORMOTENSIVE YOUNG SUBJECTS
2001
Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)
2009
The role of platelets in blood coagulation—effects of platelet agonists and GPIIb/IIIa inhibitors studied by free oscillation rheometry
2002 StandoutNobel
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
2003 Standout
Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity
2016
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
2014 Standout
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
2005 Standout
Uric Acid and Cardiovascular Risk
2008 Standout
Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications
2002
Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents
2017 Standout
Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
2011
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
2007
Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials
2009
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases
2009 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Effects of inhibition of P2Y1 and P2Y12 on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry
2003 StandoutNobel
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Pharmacological control of platelet function
2001
Studies of fibrinogen binding to porcine platelets by flow cytometry: a method for studies of porcine platelet activation
2002 StandoutNobel
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial
2003
β-Blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial
2002
Rosuvastatin
2004
Management of metabolic syndrome: statins
2004
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
2009 Standout
A strategy to reduce cardiovascular disease by more than 80%
2003 Standout
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2004 Standout
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
2001 Standout
Special Invited Papers Section: Therapeutic Equivalence – Clinical Issues and Statistical Methodology in Noninferiority Trials
2005
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Integrins
2002 Standout
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
2004 Standout
Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization
2000
The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care
2008
Thiazide Diuretics Exacerbate Fructose-Induced Metabolic Syndrome
2007
Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database
2013
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
2003 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes
2001
Systematic Review: Antihypertensive Drug Therapy in Black Patients
2004
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
2005 Standout
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
2019 Standout
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
A Whole Blood Assay of Inhibition of Platelet Aggregation by Glycoprotein IIb/IIIa Antagonists: Comparison with other Aggregation Methodologies
1999
Interventions for enhancing medication adherence
2014 Standout
The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology
2017 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia
2008
The Metabolic Syndrome
2008 Standout
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial
2000
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy
2003
2020 International Society of Hypertension Global Hypertension Practice Guidelines
2020 Standout
Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers: Novel Parenteral and Potential Oral Antithrombotic Agents
2000
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists
2001
Works of Brian Bryzinski being referenced
Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
2006
First‐Line Therapy Option with Low‐Dose Bisoprolol Fumarate and Low‐Dose Hydrochlorothiazide in Patients with Stage I and Stage II Systemic Hypertension
1995
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
2003
Bisoprolol, a once‐a‐day beta‐blocking agent for patients with mild to moderate hypertension
1994
Comparison of Effects of Controlled Onset Extended Release Verapamil at Bedtime and Nifedipine Gastrointestinal Therapeutic System on Arising on Early Morning Blood Pressure, Heart Rate, and the Heart Rate–Blood Pressure Product11A list of study investigators appears in the Appendix A.
1998
Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim phamacodynamic results of the SOAR study
1998
Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban
1998
A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus
2007